Cancer Immunotherapy: an Emerging Paradigm
|
|
- Thomasina Parks
- 6 years ago
- Views:
Transcription
1 Cancer Immunotherapy: an Emerging Paradigm Branimir I. Sikic, MD Professor of Medicine Stanford University Nevada Cancer Control Summit Reno, November 6, 217
2 T-Cell Response: Second Signals to Accelerate or Brake Activating Signals Inhibitory Signals (brakes) * CD28 OX4 GITR CD137 T cell CTLA-4 PD-1 TIM-3 Releasing these brakes activates T-cells against cancers CD27 BTLA HVEM VISTA LAG-3 T-Cell Stimulation T-Cell Inhibition Mellman I, et al. Nature. 211;48:
3 Mechanism of Action: Ipilimumab releases the CTLA-4 brake on T-cells Jim Allison M.D. Anderson 3
4 Mechanism of Action: PD-1 and PD-L1 antibodies release brakes on T-cells and enable antitumor cytotoxicity 4
5 FDA approval status of Immune CTLA-4 and PD-1 Checkpoint Inhibitors Ipilumumab (CTLA-4): Melanoma (211) Pembrolizumab (PD-1): Melanoma (214) Non-small Cell Lung (215) Head and Neck cancers (216) Microsatellite-Instability High (MSI) solid tumors (217) Bladder cancers (217) Hodgkin lymphoma (217) Nivolumab (PD-1): Melanoma (214) Non-small Cell Lung (215) Renal (215) Hodgkin Lymphoma (216) Head and Neck Squamous (216) Bladder cancers (217)
6 FDA approval status of PD-L1 Checkpoint Inhibitors Atezolizumab: Urothelial cancers (216) Non-small Cell Lung Cancers (NSCLC), (216) Avelumab: NSCLC (216) Merkel Cell cancers (217) Durvalumab: Urothelial cancers (217)
7 Melanoma
8 Nivolumab anti-pd-1 therapy in Metastatic Melanoma: Spider plot of tumor size over time in individuals Topalian et al., NEJM 366: , 212
9 Updated Results From a Phase III Trial of Nivolumab Combined With Ipilimumab in Treatment-naïve Patients With Advanced Melanoma (Checkmate 67) Jedd D. Wolchok, 1 Vanna Chiarion-Sileni, 2 Rene Gonzalez, 3 Piotr Rutkowski, 4 Jean-Jacques Grob, 5 C. Lance Cowey, 6 Christopher D. Lao, 7 Dirk Schadendorf, 8 Pier Francesco Ferrucci, 9 Michael Smylie, 1 Reinhard Dummer, 11 Andrew Hill, 12 John Haanen, 13 Michele Maio, 14 Grant McArthur, 15 Dana Walker, 16 Joel Jiang, 16 Christine Horak, 16 James Larkin, 17* F. Stephen Hodi 18* 1 Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research and Weill Cornell Medical College, New York, NY, USA; 2 Oncology Institute of Veneto IRCCS, Padua, Italy; 3 University of Colorado Cancer Center, Denver, CO, USA; 4 Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland; 5 Hospital de la Timone, Marseille, France; 6 Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Research, Dallas, TX, USA; 7 University of Michigan, Ann Arbor, MI, USA; 8 Department of Dermatology, University of Essen, Essen, Germany; 9 European Institute of Oncology, Milan, Italy; 1 Cross Cancer Institute, Edmonton, Alberta, Canada; 11 Universitäts Spital, Zurich, Switzerland; 12 Tasman Oncology Research, QLD, Australia; 13 Netherlands Cancer Institute, Amsterdam, The Netherlands; 14 University Hospital of Siena, Siena, Italy; 15 Peter MacCallum Cancer Centre, Victoria, Australia; 16 Bristol-Myers Squibb, Princeton, NJ, USA; 17 Royal Marsden Hospital, London, UK; 18 Dana-Farber Cancer Institute, Boston, MA, USA. *Contributed equally to the study 9
10 CA29-67: Study Design Design Randomized, double-blind, phase III study to compare NIVO+IPI or NIVO alone to IPI alone N=314 NIVO 1 mg/kg + IPI 3 mg/kg Q3W for 4 doses then NIVO 3 mg/kg Q2W Unresectable or Metatastic Melanoma Previously untreated 945 patients Randomize 1:1:1 Stratify by: Tumor PD-L1 expression* BRAF mutation status AJCC M stage N=316 NIVO 3 mg/kg Q2W + IPI-matched placebo Treat until progression** or unacceptable toxicity N=315 IPI 3 mg/kg Q3W for 4 doses + NIVO-matched placebo *Verified PD-L1 assay with 5% expression level was used for the stratification of patients; validated PD-L1 assay was used for efficacy analyses. **Patients could have been treated beyond progression under protocol-defined circumstances. 1
11 Study Endpoints: NIVO+IPI or NIVO vs IPI Co-primary endpoints: Progression-free survival (PFS) and overall survival (OS) Secondary and exploratory endpoints: Objective response rate (ORR) by RECIST v1.1 Efficacy by tumor PD-L1 expression level Safety profile (in patients who received 1 dose of study drug) Current analysis: Efficacy and safety update with follow-up of at least 18 months OS remains immature 11
12 Progression-Free Survival Median PFS, months (95% CI) HR (99.5% CI) vs. IPI NIVO + IPI (N=314) NIVO (N=316) IPI (N=315) 11.5 ( ) 6.9 ( ) 2.9 ( ).42 (.31.57)*.55 (.43.76)* -- Progression-free Percentage Survival of PFS (%) HR (95% CI) vs. NIVO 49% 42%.76 (.6.92)** 46% 39% *Stratified log-rank P<.1 vs. IPI **Exploratory endpoint 2 1 NIVO+IPI NIVO IPI 18% % PFS per Investigator (months) Number of patients at risk: Nivolumab + Ipilimumab Nivolumab Ipilimumab Database lock Nov
13 Response To Treatment NIVO + IPI (N=314) NIVO (N=316) IPI (N=315) ORR, % (95% CI)* Two-sided P value vs IPI <.1 <.1 -- Best overall response % Complete response Partial response Stable disease Progressive disease Unknown Median duration of response, months (95% CI) NR Ongoing response among responders, % *By RECIST v1.1. NR = not reached. Database lock Nov
14 Progression-free Survival by Tumor PD-L1 Expression Tumor PD-L1 Expression Level <5% Tumor PD-L1 Expression Level 5% Median PFS, months (95% CI) HR (95% CI) vs NIVO NIVO + IPI (N=21) 11.1 ( ).74 (.58.96)* NIVO (N=28) 5.3 ( ) IPI (N=22) 2.8 ( ) Median PFS, months (95% CI) HR (95% CI) vs. NIVO NIVO + IPI (N=212) NR (9.7 NR).87 ( )* NIVO (N=218) 22. (8.9 NR) IPI (N=215) 3.9 ( ) Percentage of PFS Percentage of PFS NIVO + IPI 2 NIVO + IPI 1 NIVO IPI 1 NIVO IPI PFS (months) PFS (months) Number of patients at risk: NIVO + IPI Number of patients at risk: NIVO + IPI NIVO NIVO IPI IPI For the original PD-L1 PFS analysis, the descriptive hazard ratio comparing NIVO+IPI vs NIVO was.96, with a similar median PFS in both groups (14 months) Database lock Nov
15 Response to Treatment by Tumor PD-L1 Expression* NIVO+IPI NIVO IPI PD-L1 ( 5%) PD-L1 (<5%) ORR, % (95% CI) Median Duration of Response (months) ORR, % (95% CI) Median Duration of Response (months) NR 2.7 NR NR *Pre-treatment tumor specimens were centrally assessed by PD-L1 immunohistochemistry (using a validated BMS/Dako assay). Database lock Nov
16 Safety Summary Patients reporting event, % Treatment-related adverse event (AE) Any Grade NIVO+IPI (N=313) Grade 3-4 Any Grade NIVO (N=313) Grade 3-4 Any Grade IPI (N=311) Grade Treatment-related AE 68.8% leading of to patients who discontinued 39 NIVO+IPI 31 due 11 to treatment-related 7 15AEs achieved 14 a response discontinuation Treatment-related.3.3 death* *One reported in the NIVO group (neutropenia) and one in the IPI group (colon perforation) Database lock Nov
17 Most Common Treatment-related Select AEs Any Grade NIVO+IPI (N=313) Grade 3-4 Any Grade NIVO (N=313) Grade 3-4 Any Grade IPI (N=311) Grade 3-4 Skin AEs, % Rash Pruritus Gastrointestinal AEs, % Diarrhea Colitis Endocrine AEs, % Hypothyroidism Hyperthyroidism Hepatic AEs, % Elevated ALT Elevated AST Pulmonary AEs, % Pneumonitis Renal AEs, % Elevated creatinine Immune-modulating medicines were used to manage adverse events and led to resolution rates of immune mediated AEs in the vast majority (>85%) of patients Database lock Nov
18 Conclusions NIVO+IPI and NIVO alone significantly improved PFS and ORR versus IPI alone, in patients with untreated advanced melanoma The combination resulted in greater PFS and ORR than NIVO alone, including patients with poor prognostic factors Majority of treatment-related AEs resolved with immunemodulating medications 18
19 Squamous Cell Carcinomas of the Head and Neck
20 Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Platinum Therapy: Overall Survival 1 Median OS, mo (95% CI) HR (97.73% CI) P-value Overall Survival (% of patients) Nivolumab (n = 24) 7.5 (5.5, 9.1) Investigator s Choice (121) 5.1 (4., 6.).7 (.51,.96) 1-year OS rate (95% CI) 36.% (28.5, 43.4) Months 16.6% (8.6, 26.8) No. at Risk Nivolumab Investigator s Choice
21 Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Platinum Therapy Overall Survival by Tumor PD-L1 Expression 1 1 PD-L1 1% PD-L1 < 1% HR (95% CI) 8 HR (95% CI) Overall Survival (% of patients) Investigator s Choice (n = 61).55 (.36,.83) Nivolumab (n = 88) Overall Survival (% of patients) (.54, 1.45) Nivolumab (n = 73) Investigator s Choice (n = 38) No. at Risk Months Months Nivolumab Investigator s Choice
22 Treatment-Related Adverse Events Nivolumab in R/M SCCHN After Platinum Therapy Event Any grade n (%) Nivolumab (n = 236) Grade 3 4 n (%) Any grade n (%) Investigator s Choice (n = 111) Grade 3 4 n (%) Any treatment-related AE 139 (58.9) 31 (13.1) 86 (77.5) 39 (35.1) Fatigue 33 (14.) 5 (2.1) 19 (17.1) 3 (2.7) Nausea 2 (8.5) 23 (2.7) 1 (.9) Diarrhea 16 (6.8) 15 (13.5) 2 (1.8) Anemia 12 (5.1) 3 (1.3) 18 (16.2) 5 (4.5) Asthenia 1 (4.2) 1 (.4) 16 (14.4) 2 (1.8) Mucosal inflammation 3 (1.3) 14 (12.6) 2 (1.8) Alopecia 14 (12.6) 3 (2.7) Skin 37 (15.7) 14 (12.6) 2 (1.8) Endocrine 18 (7.6) 1 (.4) 1 (.9) Gastrointestinal 16 (6.8) 16 (14.4) 2 (1.8) Hepatic 5 (2.1) 2 (.8) 4 (3.6) 1 (.9) Pulmonary 5 (2.1) 2 (.8) 1 (.9) Hypersensitivity/infusion reaction 3 (1.3) 2 (1.8) 1 (.9) Renal 1 (.4) 2 (1.8) 1 (.9)
23 Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck After Platinum Therapy: Conclusions Nivolumab is the first agent to demonstrate a significant improvement in survival in patients with SCCHN who progress after platinum-based therapy Nivolumab doubled the 1-year survival rate: 36% with nivolumab compared to 17% for investigator s choice therapy Nivolumab demonstrated survival benefit regardless of PD-L1 expression or p16 status There were fewer treatment-related adverse events with nivolumab vs investigator s choice therapy Nivolumab is a new standard-of-care option for patients with R/M SCCHN after platinum-based therapy
24 Non-Small Cell Lung Cancers
25 Nivolumab is superior to docetaxel in previously treated patients with NSCLC NEJM 373: , 215
26 Failure of first-line immunotherapy with nivolumab versus chemotherapy in NSCLC ( CheckMate-26 ) Primary endpoint: Progression free survival 4.2 m for nivo and 5.9 m for chemotherapy 423 patients PD-L1 expression > 5% Carbone et al., NEJM 217; 376:
27 Pembrolizumab versus platinum-based chemotherapy first line in 35 NSCLC patients with high PD-L1 expression ( Keynote-24) Subset (25-3%) of patients with very high (> 5%) PD-L-1 expression PFS 1.3 m for pembrolizumab vs. 6. m for chemotherapy HR for survival.6 in favor of pembro vs chemo NEJM 216; 375:
28 Reck ESMO 216
29 Pembrolizumab versus platinum-based chemotherapy first line in NSCLC patients with high PD-L1 expression ( Keynote-24 )
30 Keynote 24 Take Home First major change in treatment of first line since megfr inhibitors Establishes mono-immunotherapy as initial treatment Applies to about 3% of first line NSCLC patients (very high PDL-1) Caveat: 5% of control pts did not cross over, so Overall Survival (OS) might not reflect real world Leaves many unanswered questions: Dose? Duration of therapy?
31 Combing Two Different Checkpoint Inhibitors in NSCLC CheckMate 12: Safety and Efficacy of First line Nivolumab and Ipilimumab in Advanced NSCLC Presented By Matthew Hellmann at 216 ASCO Annual Meeting
32 Pilot Study Results Nivolumab Plus Ipilimumab in First-line NSCLC:<br />Kinetics of Response Presented By Matthew Hellmann at 216 ASCO Annual Meeting
33 Nivolumab Plus Ipilimumab in First-line NSCLC: Conclusions Presented By Matthew Hellmann at 216 ASCO Annual Meeting
34 Nivolumab Antitumor Activity Waterfall plots of tumor regression Max Change in Target Lesions From BL (%) Max Change in Tumor Burden From BL (%) Melanoma (n = 272) [1] Pts Advanced RCC (N = 34) [3] Pts 1 mg/kg nivolumab 1 mg/kg nivolumab Max Change in Target Lesions From BL (%) Max Change in Tumor Burden From BL (%) Stable Disease Advanced NSCLC (N = 117) [2] Pts Hodgkin s Lymphoma (N = 23) [4] Partial Response Pts Alive Dead Confirmed responders Complete Response 1. Weber JS, et al. Lancet Oncol. 215;16: Rizvi NA, et al. Lancet Oncol. 215;16: McDermott DF, et al. J Clin Oncol. 215;[Epub ahead of print]. 4.Ansell SM, et al. N Engl J Med. 215;372:
35 Pembrolizumab Antitumor Activity Waterfall plots of tumor regression Change From Baseline in Sum of Largest Diameter of Target Lesions (%) Melanoma [1] (N = 411) KEYNOTE NSCLC [2] (N = 262) KEYNOTE HNSCC [3] (N = 61) KEYNOTE-12 Change From Baseline in Sum of Largest Diameter of Target Lesions (%) Urothelial Cancer [4] (N = 33) KEYNOTE Gastric Cancer [5] (N = 39) KEYNOTE TNBC [6] (N = 32) KEYNOTE chl [7] (N = 29) KEYNOTE Robert C, et al. Lancet. 214;384: Garon EB, et al. ESMO 214. LBA Chow LQ, et al. ESMO 214. LBA O Donnell P, et al. ASCO GU 215. Abstract Muro K, et al. ASCO GI 215. Abstract Nanda R, et al. SABCS 214. Abstract S Moskowitz C, et al. ASH 214. Abstract 29.
36 Summary of Activity of PD-1/PDL-1 inhibitors Survival: Melanoma, Lung, Renal, SCCHN RR or PFS: Hodgkin s, Merkel, MSI-H Colorectal > 1% RR: Anal, Bladder, Biliary, Breast, DBLCL, Esophageal, Gastric, HCC Mesothelioma, Myeloma, NPC, Ovarian, SCLC Not active: Colorectal (MSI-L), Pancreas, Prostate 36
37
38 Immunotherapy Adverse Events Onset: Average is 6-12 weeks after initiation of therapy Can occur within days of the first dose, after several months of treatment, and after discontinuation of therapy Patient complaints are autoimmune and drugrelated until proven otherwise Rule out infections, metabolic causes, tumor effects, etc. Early recognition, evaluation, and treatment are critical Slide courtesy of Joel Neal MD/PHD
39 General Principles of Immune-related Toxicity Management Generally based on severity of symptoms Grade 1: Supportive care; +/- withhold drug Grade 2: Withhold drug, consider redosing if toxicity resolves to grade 1; low-dose corticosteroids (prednisone.5 mg/kg/day or equivalent) if symptoms do not resolve within a week Grade 3-4: Discontinue drug; high-dose corticosteroids (prednisone 1-2 mg/kg/day or equivalent) tapered over 1 month once toxicity resolves to grade 1 Slide courtesy of Joel Neal MD/PHD
40 Management of Immune Checkpoint Toxicity A Multidisciplinary Approach Dermatologist Endocrinologist Gastroenterologist Medical oncologist Pulmonologist Neurologist Slide courtesy of Jeffrey Crawford MD
41 Future Directions More than 8 trials of PD-1 inhibitors in many types of cancer Combinations with other immunotherapies, such as vaccines and other antibodies Utility in minimal disease settings, such as adjuvant therapies and consolidation for patients in clinical complete remission Predictive markers for response (PD-1, PDL-1, MSI)
42
43 Thanks to Dr. Daniel Hoth for insights and slides
44 The Future of Oncology is Bright!
45 Thank you! Questions?
Índice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationMelanoma Update Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania
Melanoma Update 2016 Lynn Schuchter, MD Abramson Cancer Center University of Pennsylvania ASCO 2016 ABSTRACT # STUDY ID AGENT OUTCOME PRESENTER 9503 KEYNOTE 001 PEMBRO 3 YR OS, PFS, ORR 9504 KEYNOTE 006
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationTHE FUTURE OF MELANOMA MANAGEMENT
THE FUTURE OF MELANOMA MANAGEMENT CHARLES M. BALCH, MD, FACS PROFESSOR OF SURGERY UNIV. OF TEXAS MD ANDERSON CANCER CENTER HOUSTON, TEXAS UNIV. OF TEXAS SOUTHWESTERN MEDICAL CENTER DALLAS, TEXAS Editor-in-Chief,
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationAttached from the following page is the press release made by BMS for your information.
June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationLights and sheds of early approval of new drugs in clinical routine. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Lights and sheds of early approval of new drugs in clinical routine Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy RCT 5-10% pts «real» patients are here Clin. Pharm. Ther. 2012
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationAttached from the following page is the press release made by BMS for your information.
September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationMANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS
MANAGEMENT OF IMMUNE-RELATED SIDE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS John B.A.G. Haanen MD PhD CONTENT OF THIS PRESENTATION General aspects of immune related adverse events related to immune checkpoint
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationNew Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors
New Era of Cancer Therapy Immuno-Oncology: PD1/PD-L1 inhibitors Farah Brasfield, MD Chair, Regional Chiefs of Oncology Kaiser Permanente Jennifer Chang, PharmD, MPH Supervisor, Drug Information Services
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationHodgkin Lymphoma Nivolumab
New Drugs In Hematology Hodgkin Lymphoma Nivolumab Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 2:10-2:25 p.m immunotherapy modalities CAR T Cells
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationHHS Public Access Author manuscript N Engl J Med. Author manuscript; available in PMC 2017 November 22.
HHS Public Access Author manuscript Published in final edited form as: N Engl J Med. 2015 July 02; 373(1): 23 34. doi:10.1056/nejmoa1504030. Combined Nivolumab and Ipilimumab or Monotherapy in Previously
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationImmune checkpoint inhibition in melanoma. John Haanen
Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Singapore 217 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationASCO 2016 * Investor Meeting June 4, *American Society of Clinical Oncology, June 3-7, 2016 ASCO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ASCO 2016 * Investor Meeting June 4, 2016 *American Society of Clinical Oncology, June 3-7, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future plans
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationImmunotherapy in Non-Small Cell Lung Cancer
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
More information